Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #856037

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations
14 874 EUR
10 612 EUR
Income taxes paid (refund), classified as operating activities
0 EUR
0 EUR
Cash flows from (used in) operating activities
18 252 EUR
9 919 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
26,000 EUR
827,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
0 EUR
265,000 EUR
Proceeds from borrowings, classified as financing activities
12 056 EUR
15 281 EUR
Repayments of borrowings, classified as financing activities
1 010 EUR
40,000 EUR
Payments of lease liabilities, classified as financing activities
785,000 EUR
549,000 EUR
Cash flows from (used in) financing activities
10 267 EUR
14 957 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
0 EUR
0 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
7 959 EUR
4 211 EUR
Cash and cash equivalents
25 620 EUR
33 579 EUR
29 368 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.